Caffeine, mental health, and psychiatric disorders
- PMID: 20164571
- DOI: 10.3233/JAD-2010-1378
Caffeine, mental health, and psychiatric disorders
Abstract
Caffeine intake is so common that its pharmacological effects on the mind are undervalued. Since it is so readily available, individuals can adjust their own dose, time of administration and dose intervals of caffeine, according to the perceived benefits and side effects of each dose. This review focuses on human studies of caffeine in subjects with and without psychiatric disorders. Besides the possibility of mild drug dependence, caffeine may bring benefits that contribute to its widespread use. These benefits seem to be related to adaptation of mental energy to the context by increasing alertness, attention, and cognitive function (more evident in longer or more difficult tasks or situations of low arousal) and by elevating mood. Accordingly, moderate caffeine intake (< 6 cups/day) has been associated with less depressive symptoms, fewer cognitive failures, and lower risk of suicide. However, its putative therapeutic effects on depression and ADHD have been insufficiently studied. Conversely, in rare cases high doses of caffeine can induce psychotic and manic symptoms, and more commonly, anxiety. Patients with panic disorder and performance social anxiety disorder seem to be particularly sensitive to the anxiogenic effects of caffeine, whereas preliminary data suggests that it may be effective for some patients with obsessive compulsive disorder (OCD). The threshold for the anxiogenic effect of caffeine is influenced by a polymorphism of the A2A receptor. In summary, caffeine can be regarded as a pharmacological tool to increase energy and effortful behavior in daily activities. More populational (cross-sectional and prospective) and experimental studies are necessary to establish the role of caffeine intake in psychiatric disorders, especially its putative efficacy on depressive mood and cognitive/attentional disorders.
Similar articles
-
Caffeine and psychiatric symptoms: a review.J Okla State Med Assoc. 2004 Dec;97(12):538-42. J Okla State Med Assoc. 2004. PMID: 15732884 Review.
-
Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline.J Alzheimers Dis. 2010;20 Suppl 1:S95-116. doi: 10.3233/JAD-2010-1408. J Alzheimers Dis. 2010. PMID: 20182043 Review.
-
[Efficacy and tolerability of escitalopram in anxiety disorders: a review].Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Encephale. 2008. PMID: 18922243 Review. French.
-
[Psychiatric and psychological aspects of premenstrual syndrome].Encephale. 2001 Nov-Dec;27(6):501-8. Encephale. 2001. PMID: 11865558 Review. French.
-
Association of the anxiogenic and alerting effects of caffeine with ADORA2A and ADORA1 polymorphisms and habitual level of caffeine consumption.Neuropsychopharmacology. 2010 Aug;35(9):1973-83. doi: 10.1038/npp.2010.71. Epub 2010 Jun 2. Neuropsychopharmacology. 2010. PMID: 20520601 Free PMC article. Clinical Trial.
Cited by 41 articles
-
Prevalence and Predictors of Depression, Anxiety and Stress Symptoms in Paramedics at Saudi Red Crescent Authority.Saudi J Med Med Sci. 2020 May-Aug;8(2):105-111. doi: 10.4103/sjmms.sjmms_227_18. Epub 2020 Apr 17. Saudi J Med Med Sci. 2020. PMID: 32587491 Free PMC article.
-
Caffeine induces neurobehavioral effects through modulating neurotransmitters.Saudi Pharm J. 2020 Apr;28(4):445-451. doi: 10.1016/j.jsps.2020.02.005. Epub 2020 Feb 17. Saudi Pharm J. 2020. PMID: 32273803 Free PMC article. Review.
-
Association between tea consumption and depressive symptom among Chinese older adults.BMC Geriatr. 2019 Sep 4;19(1):246. doi: 10.1186/s12877-019-1259-z. BMC Geriatr. 2019. PMID: 31484503 Free PMC article.
-
A Case of Psychosis and Renal Failure Associated with Excessive Energy Drink Consumption.Case Rep Psychiatry. 2019 Jul 24;2019:3954161. doi: 10.1155/2019/3954161. eCollection 2019. Case Rep Psychiatry. 2019. PMID: 31428500 Free PMC article.
-
Using caffeine on the patients as therapeutic option against treatment-resistant obsessive-compulsive disorder.J Family Med Prim Care. 2019 May;8(5):1741-1747. doi: 10.4103/jfmpc.jfmpc_93_19. J Family Med Prim Care. 2019. PMID: 31198747 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
-
Full Text Sources
-
Other Literature Sources
-
Medical
-
Research Materials